K
Kamal Hamed
Researcher at Novartis
Publications - 111
Citations - 2998
Kamal Hamed is an academic researcher from Novartis. The author has contributed to research in topics: Ceftobiprole & Malaria. The author has an hindex of 27, co-authored 110 publications receiving 2557 citations. Previous affiliations of Kamal Hamed include Stanford University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data
Elizabeth A. Ashley,Francesca T. Aweeka,Karen I. Barnes,Quique Bassat,Steffen Borrmann,Steffen Borrmann,Prabin Dahal,Prabin Dahal,Tme Davis,Philippe Deloron,Mey Bouth Denis,Abdoulaye Djimde,Jean-François Faucher,Blaise Genton,Blaise Genton,Philippe J Guerin,Kamal Hamed,Eva Maria Hodel,Eva Maria Hodel,Liusheng Huang,Jullien,Harin Karunajeewa,Harin Karunajeewa,Kiechel,Poul-Erik Kofoed,Gilbert Lefèvre,Niklas Lindegardh,Kevin Marsh,Kevin Marsh,Andreas Mårtensson,Mayfong Mayxay,Mayfong Mayxay,Rose McGready,C Moreira,Paul N. Newton,Billy Ngasala,François Nosten,Christian Nsanzabana,Christian Nsanzabana,Sunil Parikh,Ric N. Price,Pascal Ringwald,Lars Rombo,Lars Rombo,Birgit Schramm,Carol Hopkins Sibley,Kasia Stepniewska,Johan Ursing,Michèle van Vugt,Michèle van Vugt,Nicholas J. White,Lesley Workman +51 more
TL;DR: Higher, more frequent, or prolonged dosage regimens should now be evaluated in very young children, particularly if malnourished, and in patients with hyperparasitemia, as well as patients in very low transmission intensity areas with emerging parasite resistance.
Journal ArticleDOI
Single-Day, Patient-Initiated Famciclovir Therapy for Recurrent Genital Herpes: A Randomized, Double-Blind, Placebo-Controlled Trial
TL;DR: A single-day regimen of patient-initiated famciclovir treatment was well tolerated and safe, and the healing of recurrent genital herpes lesions occurred approximately 2 days faster than with placebo, adding to the potential for improving patient compliance and satisfaction with therapy.
Journal ArticleDOI
A controlled, parallel, cluster-randomized trial of community-wide screening and treatment of asymptomatic carriers of Plasmodium falciparum in Burkina Faso.
Alfred B. Tiono,Alphonse Ouedraogo,Bernhards Ogutu,Amidou Diarra,Sam A. Coulibaly,Adama Gansané,Sodiomon B. Sirima,Gregory O’Neil,Amitava Mukhopadhyay,Kamal Hamed +9 more
TL;DR: Systematic screening and treatment of asymptomatic carriers at the community level did not reduce clinical malaria incidence in the subsequent transmission season, indicating greater levels of parasite clearance are required to achieve a sustained impact in this setting.
Journal ArticleDOI
Detection of Human Immunodeficiency Virus Type 1 in Semen: Effects of Disease Stage and Nucleoside Therapy
TL;DR: The effects of clinical stage of infection and antiviral therapy on the detection of human immunodeficiency virus type 1 (HIV-1) nucleic acids in semen were investigated by the polymerase chain reaction and HIV-1 detected in 45 of 52 semen specimens was detected.
Journal ArticleDOI
The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.
Nicholas M. Anstey,Ric N. Price,Tme Davis,Harin Karunajeewa,Ivo Mueller,Umberto D'Alessandro,Achille Massougbodji,Frederic Nikiema,Jean-Bosco Ouédraogo,Halidou Tinto,Issaka Zongo,Albert Same-Ekobo,M Kone,H Menan,AO Toure,William Yavo,Poul-Erik Kofoed,Bereket Alemayehu,Daddi Jima,Elisabeth Baudin,Emmanuelle Espie,Carolyn Nabasumba,Loretxu Pinoges,Birgit Schramm,Michel Cot,Philippe Deloron,Jean-François Faucher,Jean-Paul Guthmann,Bertrand Lell,Steffen Borrmann,George O. Adjei,J Ursing,Emiliana Tjitra,Kevin Marsh,Judy Peshu,Elizabeth Juma,Bernhards Ogutu,Sabah A. Omar,Patrick Sawa,Ambrose O. Talisuna,Maniphone Khanthavong,M Mayxay,Paul N. Newton,Patrice Piola,Abdoulaye Djimde,Ogobara K. Doumbo,Bakary Fofana,Issaka Sagara,Quique Bassat,Raquel González,Clara Menéndez,Frank Smithuis,Teun Bousema,Piet A. Kager,P. F. Mens,Hdfh Schallig,I Van den Broek,M. van Vugt,Maman Laminou Ibrahim,Catherine O. Falade,Martin M Meremikwu,José Pedro Gil,Corine Karema,Ba,Babacar Faye,Oumar Faye,Gaye O,Jean Louis Ndiaye,Mbaye Pene,Doudou Sow,K Sylla,Rck Tine,Louis K. Penali,Karen I. Barnes,Lesley Workman,Angeles Lima,Ishag Adam,Nahla B Gadalla,Efm Malik,Anders Björkman,Andreas Mårtensson,Billy Ngasala,Lars Rombo,P Aliu,Stephan Duparc,Scott G. Filler,Blaise Genton,Eva Maria Hodel,Piero Olliaro,S Abdulla,Erasmus Kamugisha,Zulfiqarali Premji,Seif Shekalaghe,Elizabeth A. Ashley,Verena I. Carrara,Rose McGready,François Nosten,Abul Faiz,Sue J. Lee,Nicholas J. White,Arjen M. Dondorp,Jeff Smith,Joel Tarning,Jane Achan,Hasifa Bukirwa,Adoke Yeka,Emmanuel Arinaitwe,Sarah G. Staedke,Kamya,Fred Kironde,Chris Drakeley,Mary C. Oguike,Colin J. Sutherland,Francesco Checchi,Prabin Dahal,Jennifer A. Flegg,Philippe J Guerin,Clarissa Moreira,Christian Nsanzabana,Carol Hopkins Sibley,Kasia Stepniewska,Peter W. Gething,Si Hay,Brian Greenwood,Stephen A. Ward,P. A. Winstanley,Grant Dorsey,Bryan Greenhouse,P. Rosenthal,Anastasia Grivoyannis,Kamal Hamed,J Hwang,PS Kachur,Michael Nambozi +133 more
TL;DR: The recommended dose of artemether-lumefantrine provides reliable efficacy in most patients with uncomplicated malaria, however, therapeutic efficacy was lowest in young children from Asia and young underweight children from Africa; a higher dose regimen should be assessed in these groups.